Clinical observation of rabeprazole combined with mosapride in the treatment of reflux esophagitis
10.3969/j.issn.1005-1678.2017.06.115
- VernacularTitle:雷贝拉唑联合莫沙必利治疗反流性食管炎的疗效观察
- Author:
Qiao CHEN
;
Congling YANG
- Keywords:
reflux esophagitis;
rabeprazole;
mosapride;
curative effect;
clinical symptoms;
quality of life
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(6):304-306
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of rabeprazole combined with mosapride in the treatment of reflux esophagitis.MethodsThe clinical data of 315 patients with reflux esophagitis from December 2015 to December 2016 in our hospital were retrospectively analyzed, were randomly divided into two groups according to the time of admission.The control group (157 cases)was treated with rabeprazole, the observation group (158 cases) given rabeprazole combined with mosapride treatment.The clinical symptom scores before and after treatment, the effective rate of treatment, the quality of life before and one month after treatment and three months after treatment of two groups were compared.ResultsAfter treatment,the symptoms scores of the two groups were significantly lower than those before treatment, but the the scores in the observation group were significantly lower than those in the control group (P<0.05);The total effective rate was 96.2% in the observation group, which was significantly higher than that in the control group (79.0%), the difference between the two groups was statistically significant (P<0.05);The quality of life scores of the two groups were significantly higher than that before treatment, but the scores of one months after treatment and three months after treatment in observation group were significantly higher than those in control group (P<0.05).ConclusionReflux esophagitis with rabeprazole combined with mosapride treatment is significant,can better improve the clinical symptoms of patients, improve the treatment efficiency, and improve the quality of life of patients.